logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tofacitinib for chronic plaque psoriasis – second line

< Back

Tofacitinib for chronic plaque psoriasis – second line

Drugs

Skin Disease, Burns and Wound Care

April 2015


Tofacitinib is intended to be used as second line therapy for the treatment of chronic moderate-to-severe plaque psoriasis. If licensed, it will provide an additional oral treatment option for this patient group. Tofacitinib is a novel janus kinase (JAK) inhibitor that inhibits JAK1, 2 and 3 in vitro, with functional specificity for JAK1 and 3. Inhibition of JAK1 and 3 blocks signalling of several cytokines which are required for lymphocyte activation, proliferation, and function, and therefore may result in modulation of the immune response. Tofacitinib does not currently have Marketing Authorisation in the EU for any indication.
An estimated 900,000 people have psoriasis in England, with around 90% of these being plaque psoriasis. Approximately 20% have moderate-to-severe disease. Plaque psoriasis is characterised by well-delineated red scaly plaques on the skin that vary in extent from a few patches to generalised involvement. The plaques are often painful and severely itchy, with flare-ups triggered by factors such as stress, anxiety, hormonal changes, or certain infections or medications. Due to the visible nature of psoriasis, those affected may experience profound function, psychological, and social morbidity, and as a result may suffer unemployment, social isolation, and depression.
Topical treatments are offered as first line therapy, followed by phototherapy and/or systemic therapies as second line treatment, and biological therapies as third line regimes. Tofacitinib is currently in a number of phase III clinical trials comparing its effect on psoriasis severity against treatment with placebo, and etanercept.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts